NO20085060L - Triazolpyrazinderivater anvendelige som anti-cancermidler - Google Patents

Triazolpyrazinderivater anvendelige som anti-cancermidler

Info

Publication number
NO20085060L
NO20085060L NO20085060A NO20085060A NO20085060L NO 20085060 L NO20085060 L NO 20085060L NO 20085060 A NO20085060 A NO 20085060A NO 20085060 A NO20085060 A NO 20085060A NO 20085060 L NO20085060 L NO 20085060L
Authority
NO
Norway
Prior art keywords
cancer agents
derivatives useful
pyrazine derivatives
triazole
compounds
Prior art date
Application number
NO20085060A
Other languages
English (en)
Inventor
Hengmiao Cheng
Mitchell David Nambu
Mary Catherine Johnson
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Robert Steven Kania
Phuong Thi Quy Le
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20085060L publication Critical patent/NO20085060L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) eller et farmasøytisk akseptabelt salt derav, hvori R1, R2, R3 og R4 er som definert heri. Oppfinnelsen angår også farmasøytiske sammensetninger som inneholder forbindelsene med formel I, og fremgangsmåter for behandling av hyperproliferative forstyrrelser hos et pattedyr ved administrering av forbindelsene med formel I.
NO20085060A 2006-05-11 2008-12-03 Triazolpyrazinderivater anvendelige som anti-cancermidler NO20085060L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06
PCT/IB2007/001142 WO2007132308A1 (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
NO20085060L true NO20085060L (no) 2008-12-03

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085060A NO20085060L (no) 2006-05-11 2008-12-03 Triazolpyrazinderivater anvendelige som anti-cancermidler

Country Status (32)

Country Link
US (2) US7732604B2 (no)
EP (1) EP2018383B1 (no)
JP (1) JP4377962B2 (no)
KR (1) KR101099161B1 (no)
CN (1) CN101443331A (no)
AP (1) AP2008004674A0 (no)
AR (1) AR060994A1 (no)
AT (1) ATE532785T1 (no)
AU (1) AU2007251283A1 (no)
BR (1) BRPI0711809A2 (no)
CA (1) CA2651363C (no)
CR (1) CR10383A (no)
EA (1) EA016204B1 (no)
EC (1) ECSP088871A (no)
ES (1) ES2376913T3 (no)
GE (1) GEP20115174B (no)
GT (1) GT200700039A (no)
HN (1) HN2007015177A (no)
IL (1) IL194813A0 (no)
MA (1) MA30411B1 (no)
ME (1) MEP36508A (no)
MX (1) MX2008014399A (no)
NL (1) NL2000613C2 (no)
NO (1) NO20085060L (no)
NZ (1) NZ572361A (no)
PE (1) PE20080067A1 (no)
RS (1) RS20080533A (no)
TN (1) TNSN08445A1 (no)
TW (1) TWI346115B (no)
UY (1) UY30334A1 (no)
WO (1) WO2007132308A1 (no)
ZA (1) ZA200809020B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
PE20091468A1 (es) * 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
CN102014631A (zh) * 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2298731A4 (en) * 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
JP2012511575A (ja) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
PE20211639A1 (es) 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
DK2435443T3 (da) * 2009-05-28 2013-10-28 Vertex Pharma Aminopyrazoltriazolothiadiazolhæmmere af c-met-proteinkinase
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) * 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
EP3450432A1 (en) * 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
CN105968115B (zh) * 2013-04-17 2018-11-09 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用
CN106928232B (zh) * 2015-12-31 2019-07-09 上海医药集团股份有限公司 喹啉类化合物及其盐的晶型、制备方法、组合物与应用
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
US12258365B2 (en) * 2018-12-14 2025-03-25 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2025098425A1 (zh) * 2023-11-09 2025-05-15 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US9697529B2 (en) 2012-03-13 2017-07-04 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
AR060994A1 (es) 2008-07-30
HN2007015177A (es) 2010-06-09
NL2000613C2 (nl) 2007-11-20
MX2008014399A (es) 2008-11-27
US20100105656A1 (en) 2010-04-29
ES2376913T3 (es) 2012-03-20
MA30411B1 (fr) 2009-05-04
WO2007132308A1 (en) 2007-11-22
CR10383A (es) 2008-11-11
IL194813A0 (en) 2009-08-03
TWI346115B (en) 2011-08-01
MEP36508A (en) 2011-02-10
TW200804384A (en) 2008-01-16
CA2651363A1 (en) 2007-11-22
CN101443331A (zh) 2009-05-27
US20070265272A1 (en) 2007-11-15
EA200870423A1 (ru) 2009-04-28
EP2018383B1 (en) 2011-11-09
ATE532785T1 (de) 2011-11-15
CA2651363C (en) 2011-07-12
GEP20115174B (en) 2011-03-10
NZ572361A (en) 2012-02-24
GT200700039A (es) 2008-06-02
EP2018383A1 (en) 2009-01-28
ECSP088871A (es) 2008-12-30
TNSN08445A1 (fr) 2010-04-14
AP2008004674A0 (en) 2008-12-31
PE20080067A1 (es) 2008-03-10
EA016204B1 (ru) 2012-03-30
JP4377962B2 (ja) 2009-12-02
BRPI0711809A2 (pt) 2011-12-06
JP2009536636A (ja) 2009-10-15
AU2007251283A1 (en) 2007-11-22
KR20090006187A (ko) 2009-01-14
US7732604B2 (en) 2010-06-08
ZA200809020B (en) 2009-12-30
KR101099161B1 (ko) 2011-12-27
RS20080533A (sr) 2009-09-08
UY30334A1 (es) 2008-01-02

Similar Documents

Publication Publication Date Title
WO2007138472A3 (en) Triazolopyridazine derivatives
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
NO20082496L (no) Pyrazinderivater
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
NO20074703L (no) Antibakterielle piperidinderivater
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
WO2009155121A3 (en) Inhibitors of pi3 kinase
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
EA200600892A1 (ru) Новые хинолиновые производные
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
DOP2006000271A (es) Sales, profármacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]pirimidin-5-carbonil)-2-metoxi-fenil]-3-(2,4-dicloro-fenil)-urea
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application